Vor Biopharma (VOR) Change in Accured Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Change in Accured Expenses data on file, last reported at -$9.1 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 562.78% year-over-year to -$9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 4.39% YoY) and the FY2025 annual result came in at $10.9 million, up 387.73% from the prior year.
• Change in Accured Expenses fell to -$9.1 million in Q1 2026 per VOR's latest filing, from $6.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.2 million in Q4 2025 and bottomed at -$9.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $485000.0 (2024), against an average of $472647.1.
• The widest annual swing landed in 2022, when Change in Accured Expenses jumped 2200.0%; it then tumbled 2720.45% in 2024.
• Tracing VOR's Change in Accured Expenses over 5 years: stood at $1.7 million in 2022, then plunged by 89.61% to $172000.0 in 2023, then surged by 2043.6% to $3.7 million in 2024, then jumped by 68.32% to $6.2 million in 2025, then slumped by 246.63% to -$9.1 million in 2026.
• Per Business Quant, the three latest VOR Change in Accured Expenses figures stand at -$9.1 million (Q1 2026), $6.2 million (Q4 2025), and $5.0 million (Q3 2025).

Peer Comparison